Aayush GuptaMultibacillary leprosy, treatment monitoring
Skin assessment chart and plasma PGL-I
Dr Aayush Gupta is the principal investigator at Dr. D.Y. Patil Medical College, Hospital and Research Centre, Pimpri, Pune for a phase 0 study of skin assessment chart and plasma PGL-I in multibacillary leprosy, treatment monitoring, sponsored by Johnson & Johnson. Status: opens October 2026.
- Phase
- Phase 0
- Sponsor
- Johnson & Johnson
- Status
- Opening this autumn: Opens October 2026
- Principal investigator
- Dr Aayush Gupta
- Site
- Dr. D.Y. Patil Medical College, Hospital and Research Centre, Pimpri, Pune
- Condition
- Multibacillary leprosy, treatment monitoring
Official title
A Phase 0, Clinical Study to Provide Fit-For-Purpose Evidence for the Standardized Skin Assessment Chart and to Evaluate Changes in Plasma Phenolic Glycolipid-I Over Time for Treatment Monitoring in Multibacillary Leprosy Patients
Research programme
He is the principal investigator at Dr. D.Y. Patil on LIGHT, a Phase 3 Johnson & Johnson trial of bedaquiline in multibacillary leprosy, and on a Phase 0 study of plasma PGL-I for treatment monitoring. His clinical papers cover leprosy, the differential diagnosis of leonine facies, scrofuloderma and nodular secondary syphilis with granulomatous inflammation.
Related papers
15 in this area
- Comment on Case Series of Kaposi’s Varicelliform Eruption Associated with Underlying Primary DermatosesIndian Journal of Dermatology2026Senior authorDOI
- Global, regional, and national burden of HIV/AIDS, 1990–2023, with the estimated burden attributable to intimate partner violence and forecasted impacts of funding cuts through 2030: results from the Global Burden of Disease Study 2023The Lancet HIV2026DOI
- Revisiting Leonine Facies: Toward More Inclusive Differential DiagnosesIndian Dermatology Online Journal2026Senior authorDOI
- Internalized stigma, not disability, drives quality‐of‐life loss in leprosy: A structural analysisJournal of the European Academy of Dermatology and Venereology2026Senior authorDOI
- A Within-Person Randomized Controlled Pilot Study to Evaluate the Ability of a Point-of-Care Artificial Intelligence-Enabled Multispectral Imaging Device to Manage Leg Ulcers in LeprosyAdvances in Skin & Wound Care2025Senior authorDOI
- Borderline Tuberculoid LeprosyJEADV Clinical Practice2025Senior authorDOI
Other trials
- Placebo-controlled · Sun PharmaSevere alopecia areata in adolescentsSubmitted to DCGI
- Phase 2 · Ahammune BiosciencesNon-segmental vitiligoOpens October 2026
- Observational · Systopic LaboratoriesHair health in adultsOpens October 2026
- Phase 4 · Johnson & JohnsonPsoriasisOpens November 2026
- Phase 3 · Johnson & JohnsonMultibacillary leprosyUnder way since January 2025
- Registry · PfizerAtopic dermatitis, alopecia areata and vitiligoStarted March 2025, completed